HeartWare International, Inc. (Nasdaq: HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, ...

DUBLIN., The United States Food and Drug Administration (FDA) has classified Medtronic plc's recent voluntary urgent field action related to the HeartWare(TM) HVAD(TM) System unexpected power source ...

Medtronic's HeartWare HVAD pump system has been hit with a slew of recalls in recent months and the rate of device malfunction reports documented since it's been on the market in an FDA database ...

A year after pulling its HeartWare Ventricular Assist Device (HVAD) System from the market, Medtronic is still dealing with regulatory issues associated with the device. In a recent update, FDA called ...

Medtronic is recalling one lot of batteries that power its HeartWare Ventricular Assist Device (HVAD) System due to a welding defect that can cause them to malfunction. The US Food and Drug ...

FRAMINGHAM, Mass. and SYDNEY, Jan. 9, 2012 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies ...

HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, ...

The US Food and Drug Administration (FDA) has identified a recall by Medtronic of the HeartWare Ventricular Assist Device (HVAD) as Class I, indicating risk for serious injuries or death, because of ...

The HeartWare system is now off the table for left ventricular assist device (LVAD) candidates with advanced heart failure, the FDA announced. Medtronic is halting the global distribution and sale of ...

Company Has Initiated a Post-Approval Study of Heart Failure Management Best Practices to Further Demonstrate Improved Patient Outcomes DUBLIN and ORLANDO, Fla. - April 5, 2019 - Medtronic plc ...